Correction to: Analysis of CF patient survival confirms STAT3 as a CF-modifying gene with changing impact over time

This is a correction to: Inga Dunsche, Ellen L Raddatz, Haide Ismer, Silke Hedtfeld, Stephanie Tamm, Saskia Moser, Julia Kontsendorn, Burkhard Tümmler, Sabina Janciauskiene, Anna-Maria Dittrich, Frauke Stanke, Analysis of CF patient survival confirms STAT3 as a CF-modifying gene with changing impact over time, Human Molecular Genetics, 2022, ddac221, https://doi.org/10.1093/hmg/ddac221

In the originally published version of this manuscript, Table 1 had two columns incorrectly transposed. The information under “Patients' genotype at STAT3: both STAT3Sat alleles =16 ARU” “No of patients, n (%)”, should be swapped with that under “Patients' genotype at STAT3: both STAT3Sat alleles =12 ARU” “No of patients, n (%)”.

This error has been corrected online.

Table 1

Patient survival by STAT3Sat genotype

Year of birth	No of patients	Patients’ genotype at STAT3: both STAT3Sat alleles ≥16 ARU		Patients genotype at STAT3: both STAT3Sat alleles ≤12 ARU		Patient is heterozygous at STAT3Sat		P
		No of patients, n (%)	Median survival	No of patients, n (%)	Median survival	No of patients, n (%)	Median survival
1959–1994	165a	15 (8.6%)	n.d.	66 (37.9%)	n.d.	84 (48.3%)	n.d.	n.d.
1959–1976	78	7 (8.8%)	30 years	26 (32.5%)	≈50 years	45 (56.3%)	35 years	0.023
1972–1983	75	9 (11.3%)	42 years	27 (33.8%)	36 years	39 (48.8%)	35 years	0.406
1977–1994	75	7 (8.8%)	36 years	35 (43.8%)	32 years	33 (41.3%)	37 years	0.913

^aOut of 174 p.Phe508del-CFTR homozygotes, the STAT3Sat genotype could not be resolved for eight patients. One patient carried SAT3Sat-14 on both chromosomes and thus could not be classified in either group ‘carries at least one allele STAT3Sat-16 or more ARU’ or ‘both alleles STAT3Sat-12 or less ARU’.